Get started
Author

Remi Largillier

Observed names: Largillier R, R LARGILLIER, R Largillier, R. Largillier, Rémi Largillier
Observed institutions: F. Hoffmann-La Roche AG, Inserm, Institut Gustave Roussy, Centre Hospitalier Universitaire de Besançon, Centre Georges François Leclerc, Institut de Cancérologie de Lorraine, Centre Hospitalier Universitaire de Nîmes, Centre Hospitalier de Saint-Brieuc, Centre Léon Bérard, Institut de Cancérologie de l'Ouest, Hôpital privé Clairval, Centre Eugène Marquis, Hôpital l'Archet, Centre Jean Perrin, Centre Hospitalier du Mans, Centre Oscar Lambret, Centre Azuréen de Cancérologie, Centre Hospitalier de Valence, Institut Bergonié, Hôpital Pasteur, Institut Paoli-Calmettes, Centre Antoine Lacassagne, Hôpital Tenon, Centre Hospitalier William Morey, Institut Strauss, Institut Curie
OpenAlex ID: A5110199344
Prognostic factors in 1038 women with metastatic breast cancer
2008 · R. Largillier, J.-M. Ferrero, et al. · Annals of Oncology · 367
PDF
Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
2003 · P. Fumoleau, R. Largillier, et al. · European Journal of Cancer · 302
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
2012 · A. Gonçalves, M. Gilabert, et al. · Annals of Oncology · 222
PDF
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
2012 · U Wagner, C Marth, et al. · British Journal of Cancer · 188
PDF
Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRI
2002 · C. Balu-Maestro, C. Chapellier, et al. · Breast Cancer Research and Treatment · 187
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial
2021 · Sandro Pignata, Domenica Lorusso, et al. · The Lancet Oncology · 154
A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group
2012 · P. Pautier, A. Floquet, et al. · Annals of Oncology · 136
6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
2019 · Xavier Pivot, Gilles Romieu, et al. · The Lancet · 130
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
2007 · S Beauclair, P Formento, et al. · Annals of Oncology · 121
PDF
Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial
2023 · Jean-Emmanuel Kurtz, Eric Pujade-Lauraine, et al. · Journal of Clinical Oncology · 113
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
2021 · D. Miles, E. Ciruelos, et al. · Annals of Oncology · 98
PDF
Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)
2011 · A. Lortholary, R. Largillier, et al. · Annals of Oncology · 91
Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer
2000 · Didier Cowen, Gilles Houvenaeghel, et al. · International Journal of Radiation Oncology*Biology*Physics · 89
Aromatase inhibition in male breast cancer patients: biological and clinical implications
2009 · J. Doyen, A. Italiano, et al. · Annals of Oncology · 87
Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial
2009 · J.E. Kurtz, A.-C. Hardy-Bessard, et al. · Gynecologic Oncology · 87
Epidermal growth factor receptor expression in 780 breast cancer patients: A reappraisal of the prognostic value based on an eight-year median follow-up
2001 · J.M. Ferrero, A. Ramaioli, et al. · Annals of Oncology · 54
PDF
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
2024 · P. Harter, C. Marth, et al. · Annals of Oncology · 42
PDF
Rémission complète par létrozole chez un homme traité pour un cancer du sein métastatique
2004 · A Italiano, R Largillier, et al. · La Revue de Médecine Interne · 41
Decision-making and breast cancer clinical trialsHow experience challenges attitudes
2007 · J MANCINI, J GENEVE, et al. · Contemporary Clinical Trials · 36
Prognostic Factors in 401 Elderly Women with Metastatic Breast Cancer
2014 · P. Follana, J. Barrière, et al. · Oncology · 24
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
2010 · S. Guiu, M. Liegard, et al. · Annals of Oncology · 22
Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer
2015 · Claire Falandry, Wadih Rhondali, et al. · Clinical Interventions in Aging · 21
PDF
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
2022 · Renaud Sabatier, Frédérique Rousseau, et al. · European Journal of Cancer · 20
PDF
Early versus Late Local Recurrences after Conservative Treatment of Breast Carcinoma: Differences in Primary Tumor Characteristics and Patient Outcome
2006 · A. Courdi, R. Largillier, et al. · Oncology · 20
LBA42 Olaparib vs placebo as maintenance therapy after platinum-based chemotherapy in advanced/metastatic endometrial cancer patients: The GINECO randomized phase IIb UTOLA trial
2023 · F. Joly Lobbedez, A. Leary, et al. · Annals of Oncology · 19
PDF
Works count: 94
Citation count: 3,006
H-index: 22
I10-index: 34
Year
Topic
Type